Navigation Links
Stent Studies Tied to Rapid Changes in Use
Date:7/28/2009

Fast dissemination of data may become main stimulus for change, experts say

TUESDAY, July 28 (HealthDay News) -- Rapid dissemination of new data about the risks posed by drug-eluting stents led to an almost immediate decrease in the use of the stents, according to a new report.

Drug-eluting stents are coated with drugs meant to prevent re-narrowing of coronary arteries.

An analysis of patient registries showed that between January and September 2006, about 90 percent of people who had a type of heart attack called a non-ST-elevation myocardial infarction and underwent coronary stent implantation received drug-eluting stents.

That September, a number of studies presented at a European Society of Cardiology meeting said that the risk of blood clots was higher among people who received drug-eluting stents than among those who received bare-metal stents.

By the end of March 2007, the use of drug-eluting stents had declined to 67 percent and continued to drop to 58 percent by the start of 2008, the researchers found. Their study is published online in Circulation: Cardiovascular Quality and Outcomes.

"There was a rapid change of practice patterns after these presentations in September 2006," the study's lead author, Dr. Matthew T. Roe, an associate professor of medicine at Duke University Medical Center and the Duke Clinical Research Institute in Durham, N.C., said in an American Heart Association news release. "To our knowledge, this was the most rapid change in practice patterns in cardiology. We presume it was because of rapid uptake of information."

The findings suggest that fast distribution of new information through media and scientific outlets could become the "predominant stimulus for change in practice in the future," Roe and his colleagues said.

Dr. Clyde W. Yancy, president of the American Heart Association, said in the news release that the study "demonstrates the dynamic shifts that are occurring in the distribution of medical information."

"The opportunity to widely share important findings that promptly impact practice is becoming a powerful tool to drive change," Yancy said. "The requirements for prompt but thorough peer review and nimble responsiveness to new data are evident. Managing this new health IT space will require focus, assessment and realignment."

More information

The Society for Vascular Surgery has more about angioplasty and stenting.



-- Robert Preidt



SOURCE: American Heart Association, news release, July 28, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. QHR Client Hospitals Lauded for Consistently High Quality Standards, Exceeding Patient Expectations
2. FDA Approves Boston Scientifics TAXUS(R) Liberte(R) Long Stent
3. AbbeyMoor Medical Receives FDA Approval for Design Improvements to The Spanner(TM) Prostatic Stent
4. CorNova(R) Receives CE Mark Approval for Valecor Platinum(R) Coronary Stent System
5. Abbott Receives CE Mark for Companys Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Advancing Leadership Position
6. Newest Coated Stent Does Well in Real-World Trial
7. AMA Supports Health System Reform Alternatives Consistent With Principles of Pluralism, Freedom of Choice, Freedom of Practice and Universal Access for Patients
8. Analysis of drug-eluting stents data demonstrates safety, efficacy in on-and-off-label use
9. InstaMed Achieves CAQH CORE Rules Certification, Streamlines Provider Access to Consistent Electronic Eligibility, Benefits and Patient Financial Liability Data
10. Abbott Initiates Trial of Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Building Upon Superior Outcomes from SPIRIT Family of Trials
11. Broncus Technologies Exhale Stent and Other New Devices to Prompt Robust Growth In Emphysema Treatment Market, According to Millennium Research Group
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Stent Studies Tied to Rapid Changes in Use
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... Francisco, CA (PRWEB) , ... June 24, 2016 ... ... CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive ... self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway ... call for a minimum wage raise to $12 an hour by 2020 and then adjusting ... restore the lost value of the minimum wage, assure the wage floor does not erode ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented its first-ever ... Medicine conference in Ponte Vedra Beach, FL. The awards honor the outstanding work ... Practice and Pediatric Emergency Medicine Practice. , “With this award, we recognize ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... NORTHBROOK, Ill. and BOGOTA, Colombia , June 23, 2016  Astellas today announced the ... joins Astellas Farma Brasil as the company,s second affiliate in Latin America . ... ... appointed General Manager of Astellas Farma Colombia ... ...
Breaking Medicine Technology: